Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Bioventus Inc.
  6. Summary
    BVS   US09075A1088

BIOVENTUS INC.

(BVS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
14.23(c) 14.09(c) 14.22(c) 12.86(c) 12.74(c) Last
73 300 115 688 146 608 133 583 94 371 Volume
+0.49% -0.98% +0.92% -9.56% -0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 430 M - -
Net income 2021 72,7 M - -
Net Debt 2021 209 M - -
P/E ratio 2021 7,88x
Yield 2021 -
Sales 2022 563 M - -
Net income 2022 56,2 M - -
Net Debt 2022 162 M - -
P/E ratio 2022 14,0x
Yield 2022 -
Capitalization 757 M 757 M -
EV / Sales 2021 2,24x
EV / Sales 2022 1,63x
Nbr of Employees 900
Free-Float 49,4%
More Financials
Company
Bioventus Inc is a global medical device company. The Company is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint... 
More about the company
Ratings of Bioventus Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOVENTUS INC.
01/12BIOVENTUS : Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue - Form 8-K
PU
01/12BIOVENTUS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/11Bioventus Sees Higher Fiscal Q4 Revenue, Boosts FY Revenue Guidance
MT
01/11Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue
GL
01/11Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue
GL
01/11Bioventus Inc. provides Earnings Guidance for the Fourth Quarter and Full-Year Ending D..
CI
2021Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021BIOVENTUS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Bioventus Inc. Announces Board Changes, Effective as of January 1, 2022
CI
2021Bioventus Appoints Michelle McMurry-Heath to Board of Directors
AQ
2021Bioventus Inc. Appoints Michelle Mcmurry-Heath to Board of Directors, Effective January..
CI
2021Bioventus Gets FDA Clearance for BoneScalpel Access Handpiece
MT
2021Bioventus Receives US FDA Clearance for BoneScalpel® Access™
GL
2021Bioventus Inc. Receives US FDA Clearance for BoneScalpel Access
CI
2021BIOVENTUS INC.(NASDAQGS : BVS) added to NASDAQ Biotechnology Index
CI
More news
News in other languages on BIOVENTUS INC.
01/11Bioventus enregistre une hausse de son chiffre d'affaires au quatrième trimestre fiscal..
01/11Bioventus Inc. fournit des prévisions de résultats pour le quatrième trimestre et l'exe..
2021Bioventus Inc. annonce des changements au sein de son conseil d'administration, qui ent..
2021Bioventus Inc. nomme Michelle Mcmurry-Heath au conseil d'administration, à compter du 1..
2021Bioventus obtient l'autorisation de la FDA pour la pièce à main BoneScalpel Access
More news
Analyst Recommendations on BIOVENTUS INC.
More recommendations
Chart BIOVENTUS INC.
Duration : Period :
Bioventus Inc. Technical Analysis Chart | BVS | US09075A1088 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 12,74 $
Average target price 21,00 $
Spread / Average Target 64,8%
EPS Revisions
Managers and Directors
Kenneth Michael Reali Chief Executive Officer & Director
Gregory O. Anglum Chief Financial Officer & Senior Vice President
William A. Hawkins Chairman
Miguel O. Beltrán-Delgado Senior Vice President-Operations
Mary Kay Ladone Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOVENTUS INC.-12.08%757
MASIMO CORPORATION-27.26%11 761
GETINGE AB-16.68%9 654
PENUMBRA, INC.-25.84%7 960
NOVOCURE LIMITED-14.21%6 687
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.-19.58%4 835